151895-74-8

Basic information

• Product Name: Methanesulfonic acid, 1,1,1-trifluoro-, 4-oxo-4H-1-benzopyran-7-yl ester
• Synonyms: Methanesulfonic acid, 1,1,1-trifluoro-, 4-oxo-4H-1-benzopyran-7-yl ester
• CAS NO: 151895-74-8
• Molecular Formula: C₁₀H₅F₃O₅S
• Molecular Weight: 294.2039096
• Mol File: 151895-74-8.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Methanesulfonic acid, 1,1,1-trifluoro-, 4-oxo-4H-1-benzopyran-7-yl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Methanesulfonic acid, 1,1,1-trifluoro-, 4-oxo-4H-1-benzopyran-7-yl ester(151895-74-8)
• EPA Substance Registry System: Methanesulfonic acid, 1,1,1-trifluoro-, 4-oxo-4H-1-benzopyran-7-yl ester(151895-74-8)

Safety Data

• Hazardous Substances Data: 151895-74-8(Hazardous Substances Data)

Upstream product

• 59887-89-7 7-hydroxy-4H-chromen-4-one 
• 358-23-6 trifluoromethylsulfonic anhydride 

Downstream Products

• 1384433-46-8 3-(3,6-dioxocyclohexa-1,4-dienyl)-4-oxo-4H-chromen-7-yl trifluoromethanesulfonate 
• 1619229-10-5 (Z)-5-(1,2-diphenylvinyl)-4-oxo-4H-chromen-7-yl trifluoromethanesulfonate 
• 1619229-09-2 (E)-5-(1,2-diphenylvinyl)-4-oxo-4H-chromen-7-yl trifluoromethanesulfonate 
• 151884-09-2 7-[(Trifluoromethylsulfonyl)oxy]-3-phenyl-methylene-benzopyran-4-one 
• 897921-88-9 trifluoro-methanesulfonic acid 4-oxo-2-phenyl-4H-chromen-7-yl ester 

Relevant articles and documents

DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE

The present invention provides the compounds represented by formula (I): (I) or pharmaceutical salts thereof, wherein: X 1 represents oxygen atoms and the like, X 2 represents nitrogen atoms and the like, X 3 represents nitrogen atoms and the like, X 4 represents nitrogen atoms and the like, R 1 represents formula (II-1): wherein X 5 represents sulfur atoms and the like, A 1 represents carbon atoms and the like, A 2 represents nitrogen atoms and the like and A ring represents phenyl group and the like, having mGluR1 inhibiting effect, and being usefull for preventing or treating convulsion, acute pain, inflammatory pain, chronic pain, brain disorder such as cerebral infarction or transient ischemick attack, psychotic disorder such as schizophrenia, anxiety, drug dependence, Parkinson's disease, or gastrointestinal disorder.

Benzopyran and benzo-fused compounds, their preparation and their use as leukotriene B4 (LTB4) antagonists

PCT No. PCT/IB95/00401 Sec. 371 Date Apr. 9, 1997 Sec. 102(e) Date Apr. 9, 1997 PCT Filed May 26, 1995 PCT Pub. No. WO96/11920 PCT Pub. Date Apr. 25, 1996This invention relates to novel benzopyran and other benzo-fused leukotriene B4 (LTB4) antagonists and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing such compounds or a pharmaceutically acceptable salt thereof, and to methods of using such compounds as LTB4 antagonists. The compounds and the pharmaceutically acceptable salts of this invention inhibit the action of LTB4 and are therefore useful in the treatment of LTB4 induced illnesses such as inflammatory disorders including rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, psoriasis and other skin disorders such as eczema, erythema, pruritus and acne, stroke and other forms of reperfuslon injury, graft rejection, autoimmune diseases, asthma, and other conditions where marked neutrophil infiltration occurs.

BENZOPYRAN AND BENZO-FUSED COMPOUNDS, THEIR PREPARATION AND THEIR USE AS LEUKOTRIENE B4' (LTB4) ANTAGONISTS

The invention relates to novel benzopyran and other benzo-fused leukotriene B 4 (LTB 4) antagonists of formula I and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing such compounds, and to a method of using such compounds as LBT. sub.4 antagonists. The compounds of the invention inhibit the action of LTB 4 and are therefore useful in the treatment of LTB 4 induced illnesses such as inflammatory disorders including rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, psoriasis and other skin disorders such as eczema, erythema, pruitus and acne, stroke and other forms of reperfusion injury, graft rejection, autoimmune diseases, asthma and other conditions where marked neutrophil infiltration occurs. STR1